Online course offering MasterClass is a way to learn how to do your favorite things from the experts in those fields. For aspiring basketball players who want to get tips from Stephen Curry, or novice fashion designers who would love to hear from Marc Jacobs on how he launched his fashion empire, MasterClass is the place to go. The educational hub just expanded to include seven new teachers and an unlimited access option. David Rogier is the CEO of MasterClass and he joins us to explain how he got Stephen Curry and Helen Mirren to come on and do a class. Rogier explains that Mirren was an easy sell because she was eager to share her craft in a way she never had before. MasterClass has grown and improved since launch. Earlier this year, MasterClass raised $35 million in a Series C round, bringing the company to $56.4 million to date.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More